Literature DB >> 1370392

Use of fibrinogen to enhance the antitumor effect of OK-432. A new approach to immunotherapy for colorectal carcinoma.

T Monden1, H Morimoto, T Shimano, T Yagyu, M Murotani, H Nagaoka, Y Kawasaki, T Kobayashi, T Mori.   

Abstract

OK-432 (5 KE), an immunomodulatory agent prepared from an attenuated strain of Streptococcus pyogenes, was dissolved in 1 ml of aprotinin (1000 KIE) and mixed with 80 mg of fibrinogen containing Factor XIII. A single intratumoral injection of the mixture was performed preoperatively under endoscopy in 20 patients with colorectal carcinoma. Postoperative histopathologic examinations revealed the formation of fibrin fibers at the site of injection and marked infiltration of inflammatory cells into the tumor stroma on the day after injection; the formation of granulomas containing many giant cells after 4 to 7 days; and extensive regression of tumor tissue after 14 days. This study suggests that the high concentration of exogenous fibrinogen gelatinized enough to trap OK-432 in tumor stroma and that OK-432 induced granulomatous hypersensitivity to degenerate tumor stroma, thereby causing regression of the tumors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370392     DOI: 10.1002/1097-0142(19920201)69:3<636::aid-cncr2820690306>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Amelioration of chronic inflammation by ingestion of elemental diet in a rat model of granulomatous enteritis.

Authors:  S Tanaka; S Miura; H Kimura; N Ohkubo; Y Tsuzuki; D Fukumura; H Serizawa; I Kurose; M Mori; H Ishii
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

2.  Lymph flow and lymph node metastasis in esophageal cancer.

Authors:  T Nishihira; J Sayama; H Ueda; K Sugawara; R Takano; J Sagawa; M Katayama; R Shineha; K Hirayama; S Mori
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

Review 3.  Clinical trials with anticoagulant and antiplatelet therapies.

Authors:  L R Zacharski; K R Meehan; S M Algarra; F A Calvo
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 4.  Cytokine-based biotherapy of gastrointestinal tumors.

Authors:  J Buer; H Kirchner; A Schomburg; A Schüler; M Manns; E Lopez-Hänninen; S Duensing; H Poliwoda; J Atzpodien
Journal:  Clin Investig       Date:  1994-07

5.  New development of transarterial immunoembolization (TIE) for therapy of hepatocellular carcinoma with intrahepatic metastases.

Authors:  T Kanai; M Monden; M Sakon; M Gotoh; K Umeshita; Y Hasuike; H Nakano; T Monden; T Murakami; H Nakamura
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 6.  Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas.

Authors:  Xiao-Feng Sun; Hong Zhang
Journal:  Mol Cancer       Date:  2006-10-06       Impact factor: 27.401

7.  Analysis of cytotoxic activity of the CD4+ T lymphocytes generated by local immunotherapy.

Authors:  Y Katsumoto; T Monden; T Takeda; A Haba; Y Ito; E Wakasugi; T Wakasugi; M Sekimoto; T Kobayashi; H Shiozaki; T Shimano; M Monden
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

8.  Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+ Th1 killer lymphocytes.

Authors:  Y Yamaguchi; E Miyahara; A Ohshita; Y Kawabuchi; K Ohta; K Shimizu; K Minami; J Hihara; A Sawamura; T Toge
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

9.  Use of a local immunotherapy as an adjunctive tool for the generation of human monoclonal antibodies from regional lymph nodes of colonic cancer patients.

Authors:  T Yagyu; T Monden; Y Tamaki; H Morimoto; T Takeda; T Kobayashi; T Shimano; H Murakami; T Mori
Journal:  Jpn J Cancer Res       Date:  1992-01

10.  A cancer-reactive human monoclonal antibody derived from a colonic cancer patient treated with local immunotherapy.

Authors:  T Yagyu; T Monden; M Baba; Y Tamaki; T Takeda; T Kobayashi; T Shimano; Y Tsuji; H Matsushita; H Osawa
Journal:  Jpn J Cancer Res       Date:  1993-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.